Ligand Pharmaceuticals (LGND) Capital Expenditures (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported Capital Expenditures of $228000.0 for Q1 2026, up 6.54% on a YoY basis from $214000.0 in Q1 2025, and up 6.05% sequentially from $215000.0 in Q4 2025.
Ligand Pharmaceuticals (LGND) Capital Expenditures (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of Capital Expenditures data on file, last reported at $228000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 6.54% year-over-year to $228000.0; the trailing twelve-month figure through Mar 2026 stood at $229000.0 (down 88.13% YoY), and the FY2025 full-year result was $215000.0, down 88.19% from the prior year.
- Capital Expenditures improved to $228000.0 in Q1 2026, from $215000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $14.3 million in Q4 2022 to a low of -$3.1 million in Q4 2023.
- A 5-year average of $1.2 million and a median of $215000.0 in 2025 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures sank 177.34% in 2022 and soared 1578.16% in 2023, its largest moves.
- Tracing LGND's Capital Expenditures over 5 years: stood at $14.3 million in 2022, then sank by 121.71% to -$3.1 million in 2023, then jumped by 122.94% to $712000.0 in 2024, then sank by 69.8% to $215000.0 in 2025, then advanced by 6.05% to $228000.0 in 2026.
- Business Quant data shows LGND's Capital Expenditures at $228000.0 in Q1 2026, $215000.0 in Q4 2025, and -$9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 228,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 228,000.00 |
| Mar 31, 2026 | 228,000.00 |
| Dec 31, 2025 | 215,000.00 |
| Dec 31, 2025 | 215,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -205,000.00 |
| Jun 30, 2025 | -205,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Dec 31, 2024 | 712,000.00 |
| Dec 31, 2024 | 712,000.00 |
| Sep 30, 2024 | 596,000.00 |
| Sep 30, 2024 | 596,000.00 |
| Jun 30, 2024 | 408,000.00 |
| Jun 30, 2024 | 408,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | -3.10 Mn |
| Dec 31, 2023 | -3.10 Mn |